Eckert & Ziegler

The stock of Eckert und Ziegler has moved up from its yearly low but remains in a medium- to long-term downtrend. Analysts at NuWays expect an acceleration of earnings growth ahead of the Q3 results on November 12, driven by higher profitability in the Isotope Products division as well as rising sales of lutetium‑177 and licence income. Technically, the stock must overcome short-term hurdles around €13, just under €14 and the 200-day line at roughly €14.40; on the downside it needs to hold €12.50/€12.60, otherwise a retest of the yearly low at €12 looms. » More on finanzen.net

Eckert & Ziegler has signed an agreement with Dutch provider TerThera for the supply of the radionuclide terbium-161 for radioligand therapies. Terbium-161 is to be added to Eckert & Ziegler’s portfolio in Brazil to shorten the supply chain and improve regional access to theranostic solutions. The news helped the stock move off its year low, but a sustainable bottoming has not yet been achieved. » More on finanzen.net

Eckert und Ziegler has once again confirmed its targets for 2026: revenue around €320 million and adjusted EBIT of about €80 million. Investors are responding cautiously, the stock is generally moving downward and the chart technicals signal further pressure. Adjusted for currency effects and the licensing business, reported revenue and earnings show growth, but real growth is significantly more moderate. » More on finanzen.net

Geopolitical tensions in the Gulf are raising energy costs and making transport and logistics more expensive for Eckert und Ziegler, which could dampen demand. Adjusted EBIT after H1 was €33.3m, well below the annual target of around €80m, and revenue has reached €149.3m of the roughly planned €320m. Given this development, strong Q3 figures are unlikely; the stock has been in a downtrend since July and could technically fall from support at around €12.20 to just under €11, though single‑digit prices still appear distant. » More on finanzen.net

Eckert & Ziegler reported only modest revenue growth in the first half of 2026 to €149.3m, with adjusted EBIT down 6% to €33.3m. Targets for 2026 were confirmed, but reaching an adjusted EBIT of around €80m could become riskier after delays in gallium-generator deliveries caused by a cyber attack and a weak Isotope Products segment. The share fell through repeatedly tested levels and broke support at €13.30, putting a further decline toward about €12.40 at risk. Long term, the potential remains intact thanks to large actinium-225 capacities and expansion opportunities in China. » More on finanzen.net